Roivant Sciences Ltd. — Director's Dealing 2019

Dec 5, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Myovant Sciences Ltd. (MYOV)
CIK: 0001679082
Period of Report: 2019-12-02

Reporting Person: Roivant Sciences Ltd. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-12-02	Common Shares, par value $0.000017727 per share	P	113668	$18.21	Acquired	44623079	Direct
2019-12-02	Common Shares, par value $0.000017727 per share	P	65525	$18.85	Acquired	44688604	Direct
2019-12-04	Common Shares, par value $0.000017727 per share	P	72471	$17.04	Acquired	44761075	Direct
2019-12-04	Common Shares, par value $0.000017727 per share	P	2529	$17.56	Acquired	44763604	Direct

Footnotes

F1: The transaction was a series of open market purchases made in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended.

F2: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $17.57 to $18.56, inclusive. The reporting person undertakes to provide to Myovant Sciences Ltd. ("Myovant"), any security holder of Myovant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4

F3: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $18.57 to $19.00, inclusive. The reporting person undertakes to provide to Myovant, any security holder of Myovant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4

F4: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $16.55 to $17.54 inclusive. The reporting person undertakes to provide to Myovant, any security holder of Myovant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4

F5: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $17.55 to $17.56 inclusive. The reporting person undertakes to provide to Myovant, any security holder of Myovant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4